Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Low expression of Wnt-5a gene is associated with high-risk neuroblastoma

Abstract

Disseminated forms of neuroblastoma (NB), a tumor derived from neuroectodermal tissue, pose a major therapeutic challenge for pediatric oncology. By performing a comparative cDNA array analysis of metastatic neuroblasts versus primary xenograft from the human IGR-N-91 NB model, we were able to identify a set of downregulated developmental genes in metastatic neuroblasts. One of these genes was Wnt-5a, a member of the Wnt signaling pathway, known to be involved in the development of neural crest cells. Since we also found a significant decrease in Wnt-5a mRNA in unfavorable versus favorable categories in 37 primary NB tumors (P<0.007), we wondered whether retinoic acid (RA), which has a role in neural crest induction and differentiation, might reverse the aberrant negative regulation of Wnt-5a in metastatic malignant neuroblasts. Following treatment with 10 μ M RA for 6 days, the MYCN-amplified IGR-N-91 cell lines underwent neuronal differentiation as assessed by reduced MYCN gene expression and neuritic extension. In these conditions, data showed an upregulation of Wnt-5a and PKC-θ isoform expressions. Our study highlights, for the first time, the involvement of Wnt-5a, which has a role in embryonic and morphogenetic processes, in the response of malignant neuroblasts to RA. In conclusion, we demonstrated that RA, which is used in the treatment of high-risk NB patients with recurrent/residual disease in the bone marrow, is able to upregulate Wnt-5a gene expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Aigner L, Arber S, Kapfhammer JP, Laux T, Schneider C, Botteri F, Brenner HR and Caroni P . (1995). Cell, 83, 269–278.

  • Blanc E, Goldschneider D, Ferrandis E, Barrois M, Le Roux G, Leonce S, Douc-Rasy S, Bénard J and Raguénez G . (2003). Am. J. Pathol., 163, 321–331.

  • Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM and Drabkin HA . (2000). Proc. Natl. Acad. Sci. USA, 97, 12776–12781.

  • Cha KB, Douglas KR, Potok MA, Liang H, Jones SN and Camper SA . (2004). Mech. Dev., 121, 183–194.

  • Christiansen JH, Coles EG and Wilkinson DG . (2000). Curr. Opin. Cell Biol., 12, 719–724.

  • Datta R, Kojima H, Yoshida K and Kufe D . (1997). J. Biol. Chem., 272, 20317–20320.

  • Douc-Rasy S, Barrois M, Echeynne M, Kaghad, Blanc E, Raguénez G, Goldschneider D, Terrier-Lacombe MJ, Hartmann O, Moll U, Caput D and Bénard J . (2002). Am. J. Pathol., 160, 631–639.

  • Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD and Sklar J . (1991). Cell, 66, 649–661.

  • Ferrandis E, da Silva J, Riou G and Bénard J . (1994). Cancer Res., 54, 2256–2261.

  • Garcia-Castro MI, Marcelle C and Bronner-Fraser M . (2002). Science, 297, 848–851.

  • Huguet EL, Smith K, Bicknell R and Harris AL . (1995). J. Biol. Chem., 270, 12851–12856.

  • Ikeya M, Lee SM, Johnson JE, McMahon AP and Takada S . (1997). Nature, 389, 966–970.

  • Iozzo RV, Eichstetter I and Danielson KG . (1995). Cancer Res., 55, 3495–3499.

  • Jönsson M and Andersson TJ . (2001). J. Cell Sci., 11, 2043–2053.

  • Jönsson M, Dejmek J, Bendahl P and Andersson T . (2002). Cancer Res., 62, 409–416.

  • Katoh M, Hirai M, Sugimura T and Terada M . (1996). Oncogene, 13, 873–876.

  • Katoh M . (2002). Int. J. Mol. Med., 10, 683–687.

  • Körner M, Tarentino N, Pleskoff O, Lee LM and Debré P . (1995). J. Neurochem., 62, 1716–1726.

  • Kühl M, Sheldahl LC, Park M, Miller JR and Moon RT . (2000). Trends Genet., 16, 279–283.

  • Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB and Reynolds CP . (1999). N. Engl. J. Med., 341, 1165–1173.

  • Miller JR, Hocking AM, Brown JD and Moon RT . (1999). Oncogene, 18, 7860–7872.

  • Monks CRF, Kupfer H, Tamir I, Barlow A and Kupfer A . (1997). Nature, 385, 83–86.

  • Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, Wilder E, Rustgi A, Kitajewski J, Gabrielson E, Bremmes R, Franklin W and Drabkin HA . (2003). Proc. Natl. Acad. Sci. USA, 100, 10429–10434.

  • Olson DJ, Gibo DM, Saggers G, Debinski W and Kumar R . (1997). Cell Growth Differ., 8, 417–423.

  • Pahlman S, Hoehner JC, Naberg E, Hedborg F, Fagerstrom S, Gestblom C, Johansson I, Larsson U, Lavenius E, Örtoft E and Söderholm H . (1995). Eur. J. Cancer, 31A, 453–458.

  • Passalacqua M, Patrone M, Sparatore B, Melloni E and Montremoli S . (1999). Biochem. J., 337, 113–118.

  • Polakis P . (2000). Genes Dev., 14, 1837–1851.

  • Raguénez G, Lantrua V, Désiré L and Courtois Y . (1999). Biochem. Biophys. Res. Commun., 258, 745–751.

  • Reynolds CP, Matthay KK, Villablanca JG and Maurer BJ . (2003). Cancer Lett., 197, 185–192.

  • Slepko N, Patrizio M and Levi C . (1999). J. Neurosci. Res., 57, 33–38.

  • Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Pontremoli S and Melloni E . (2000a). Biochem. Biophys. Res. Commun., 275, 149–153.

  • Sparatore B, Patrone M, Passalacqua M, Pedrazzi M, Pontremoli S and Melloni E . (2000b). Biochem. Biophys. Res. Commun., 275, 589–594.

  • Taipale J and Beachy PA . (2001). Nature, 411, 349–354.

  • Tang S, Morgan KG, Parker C and Ware JA . (1997). J. Biol. Chem., 272, 28704–28711.

  • Thiele CJ, Reynolds CP and Israel MA . (1985). Nature, 313, 404–406.

  • Wakeman JA, Walsh J and Andrews PW . (1998). Oncogene, 17, 179–186.

  • Wechsler-Reya RJ and Scott MP . (1999). Neuron, 22, 103–114.

  • Weeraratna A, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M and Trent JM . (2002). Cancer Cell, 1, 279–288.

  • Yamaguchi TP, Bradley A, McMahon AP and Jones S . (1999). Development, 126, 1211–1223.

  • Zeidman R, Pettersson L, Sailaja PR, Truedsson E, Fagerström S, Pahlman S and Larsson C . (1999). Int. J. Cancer, 81, 494–501.

Download references

Acknowledgements

We thank SFCE, Dr O Hartmann, Dr Dominique Valteau-Couanet (Service de Pédiatrie), Dr Serge Koscielny (Département de Santé Publique), and Dr Marie-José Terrier-Lacombe (Service d'anatomo-pathologie). We are also grateful to Michel Barrois for his invaluable assistance in designing the gene probes, Sabrina Cantais and Nadine Béron-Gaillard for their technical assistance (all from Institut Gustave Roussy). We also thank Dr Ashani T Weeraratna and Dr Yuan Jiang from the National Human Genome Research Institute/USA for donating the PcDNA3-Wnt-5a. Edited by Englishbooster S.A. This work was supported by the Ligue contre le Cancer, Comité de Montbéliard.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gilda Raguénez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blanc, E., Roux, G., Bénard, J. et al. Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene 24, 1277–1283 (2005). https://doi.org/10.1038/sj.onc.1208255

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208255

Keywords

This article is cited by

Search

Quick links